Circulating Tumor DNA Can ID Outcomes for Patients With Melanoma

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 16, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, April 16, 2025 -- Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify patients with melanoma and a high risk for recurrence before adjuvant targeted therapy, according to a study published online April 15 in The Lancet Oncology.

Mahrukh M. Syeda, from NYU Langone Health in New York City, and colleagues examined whether ctDNA measurements could predict survival outcomes during adjuvant therapy or placebo treatment in stage III melanoma. BRAFV600E or BRAFV600K ctDNA was measured using mutation-specific droplet digital PCR assays in patients aged 18 years or older who were enrolled in the COMBI-AD trial, a double-blind study of oral dabrafenib plus oral trametinib combination therapy versus two matched placebos in resected BRAFV600-mutant stage III melanoma.

The researchers found that ctDNA was detectable in 79 of 597 baseline samples (13 percent). Patients with higher disease substages had a significantly higher ctDNA positivity rate and mutant copies per mL plasma. ctDNA detection as a binary variable was associated with worse recurrence-free survival (hazard ratios, 2.91 and 2.98 in the placebo and combination groups, respectively) and overall survival (hazard ratios, 3.35 and 4.27, respectively). Compared with interferon gamma gene expression or tumor mutational burden, baseline ctDNA was more strongly associated with survival outcomes. Compared with patients with favorable kinetics, those with adverse longitudinal ctDNA kinetics had markedly shorter median recurrence-free survival.

"These findings provide a strong rationale for additional research to improve the clinical sensitivity of these assays and advance clinical trials that investigate the clinical use of incorporating ctDNA measurements into treatment decisions," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Novartis, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-17 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords